You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

HOSPITALIZATIONS FOR INVASIVE PNEUMOCOCCAL DISEASE AMONG HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTED CHILDREN, ADOLESCENTS AND YOUNG ADULTS IN THE UNITED STATES IN THE ERA OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AND THE CONJUGATE PNEUMOCOCCAL VACCINE

Kourtis, Athena P. MD, PhD*; Ellington, Sascha MSPH*; Bansil, Pooja MPH†; Jamieson, Denise J. MD, MPH*; Posner, Samuel F. PhD*

Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3181cfb65f
Brief Reports
Abstract

We describe hospitalization trends of invasive pneumococcal disease (IPD) among human immunodeficiency virus-infected individuals <25 years of age since the introduction of highly active antiretroviral therapy (HAART) and the 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, using the Nationwide Inpatient Sample. We estimated national trends of IPD hospitalizations during 3 periods: 1994 to 1995 (pre-HAART and pre-PCV7 era); 1998 to 1999 (HAART and pre-PCV7 era); and 2004 to 2005 (HAART and early PCV7 era). The number of IPD hospitalizations among human immunodeficiency virus-infected children and youth <25 years in the United States declined by 78.7% between 1994/1995 and 2004/2005 (P = 0.03). This decrease was more pronounced among younger children.

Author Information

From the *Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA; and †CONRAD, Atlanta, GA.

Accepted for publication December 15, 2009.

The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Address for correspondence: Athena P. Kourtis, MD, PhD, MPH, DRH/NCCDPHP/CDC, 4770 Buford Highway, MS-K34, Atlanta, GA 30341. E-mail: apk3@cdc.gov.

© 2010 Lippincott Williams & Wilkins, Inc.